Physician profile
Gabriel Anders
NPI 1710392162
$3,837.54
in general payments reported to CMS, 2019-2025
25 companies · $1,224 in 2025
The $1,224 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.50 · 2021: $177 · 2022: $664 · 2023: $851 · 2024: $904 · 2025: $1,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596 · Education: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.00 |
| Education | $383.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,621.91 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Jazz Pharmaceuticals INC. | $540.86 | 2022-2025 | Xywav |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.96 | 2021-2025 | Ofev, Stiolto Respimat, Jascayd |
| Grifols USA, LLC | $215.55 | 2021-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $99.99 | 2025 | |
| Dexcom, INC. | $99.41 | 2024-2025 | Dexcom G6 Transmitter |
| Genzyme Corporation | $93.75 | 2022-2024 | |
| Glaxosmithkline, LLC. | $86.91 | 2021-2024 | Nucala |
| Genentech USA, INC. | $78.05 | 2022-2024 | Xolair |
| Insmed, INC. | $73.89 | 2023-2025 | Arikayce |
| Inspire Medical Systems, INC. | $73.52 | 2024-2025 | Inspire |
| Mylan Specialty L.P. | $60.60 | 2021-2023 | Yupelri |
| Verona Pharma, INC. | $58.80 | 2025 | Ohtuvayre |
| Noctrix Health, INC. | $51.66 | 2025 | Nidra |
| Axsome Therapeutics, INC. | $42.01 | 2025 | Sunosi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.37 | 2023 | Dupixent |
| Pfizer INC. | $27.72 | 2024 | |
| Averitas Pharma INC. | $26.18 | 2024 | Qutenza |
| Viatris Specialty LLC | $23.68 | 2025 | Yupelri |
| Zoll Respicardia, INC. | $20.30 | 2025 | Remede System |
| Novartis Pharmaceuticals Corporation | $17.07 | 2023 | |
| Sunovion Pharmaceuticals INC. | $16.50 | 2020 | |
| Ethicon INC. | $14.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.64 | 2021 | |
| Gilead Sciences, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Anders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.